GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects
- First Posted Date
- 2016-06-08
- Last Posted Date
- 2020-10-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 4
- Registration Number
- NCT02793154
- Locations
- 🇺🇸
GSK Investigational Site, Dallas, Texas, United States
In Vivo Sun Protection Factor Determination
Not Applicable
Completed
- Conditions
- Skin Care
- Interventions
- Other: Test Product GOther: Negative ControlOther: Test Product AOther: Positive ControlOther: Test Product DOther: Test Product EOther: Test Product FOther: Test Product HOther: Test Product BOther: Test Product C
- First Posted Date
- 2016-06-07
- Last Posted Date
- 2016-06-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 28
- Registration Number
- NCT02792595
- Locations
- 🇩🇪
GSK Investigational Site, Schenefeld, Schleswig-Holstein, Germany
Phase III Study of GSK1278863 in Japanese Non-dialysis (ND) and Peritoneal Dialysis (PD) Subjects With Renal Anemia
Phase 3
Completed
- Conditions
- Anaemia
- Interventions
- Drug: 1 to 4 mg tablets of GSK1278863Drug: Epoetin beta pegolDrug: 6 mg GSK1278863 tablet
- First Posted Date
- 2016-06-07
- Last Posted Date
- 2021-05-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 355
- Registration Number
- NCT02791763
- Locations
- 🇯🇵
GSK Investigational Site, Toyama, Japan
Preference Attributes of ELLIPTA Dry Powder Inhaler (DPI) and HANDIHALER DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Phase 4
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Placebo ELLIPTA deviceDrug: Placebo capsules for use in HANDIHALER deviceOther: Inhaler Preference Questionnaire Version 1Other: Inhaler Preference Questionnaire Version 2
- First Posted Date
- 2016-06-01
- Last Posted Date
- 2018-10-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 214
- Registration Number
- NCT02786927
- Locations
- 🇺🇸
GSK Investigational Site, Richmond, Virginia, United States
An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma
- First Posted Date
- 2016-05-26
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 288
- Registration Number
- NCT02783300
- Locations
- 🇳🇱
GSK Investigational Site, Rotterdam, Netherlands
Frequency of Denture Cleanser Use and Denture Cleanliness
Not Applicable
Completed
- Conditions
- Denture Cleansers
- Interventions
- Device: Denture Cleanser Daily Use PeriodDevice: Denture Cleanser Weekly Use PeriodOther: Water
- First Posted Date
- 2016-05-23
- Last Posted Date
- 2018-12-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 19
- Registration Number
- NCT02780661
- Locations
- 🇬🇧
GSK Investigational Site, Glasgow, United Kingdom
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Repeat Doses of GSK2982772 in Subjects With Psoriasis
Phase 2
Completed
- Conditions
- Psoriasis
- Interventions
- Drug: GSK2982772Drug: Placebo
- First Posted Date
- 2016-05-18
- Last Posted Date
- 2020-07-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 65
- Registration Number
- NCT02776033
- Locations
- 🇨🇦
GSK Investigational Site, Montreal, Quebec, Canada
Study to Investigate the Efficacy of an Occluding Dentifrice in Providing Relief From Dentine Hypersensitivity
Phase 4
Completed
- Conditions
- Dentin Sensitivity
- Interventions
- Other: Sodium monofluorophosphate DentifriceOther: Stannous Fluoride Dentifrice
- First Posted Date
- 2016-05-16
- Last Posted Date
- 2017-09-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 143
- Registration Number
- NCT02773758
- Locations
- 🇨🇦
GSK Investigational Site, Mississauga, Ontario, Canada
Dentine Tubule Occlusion Assessment in a Modified in Situ Model
Not Applicable
Completed
- Conditions
- Dentin Sensitivity
- Interventions
- Device: Stannous fluorideOther: Sodium monofluorophosphateOther: Mineral water
- First Posted Date
- 2016-05-11
- Last Posted Date
- 2018-06-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 26
- Registration Number
- NCT02768194
- Locations
- 🇬🇧
GSK Investigational Site, Bristol, United Kingdom
This Study Will Describe the Burden of DENgue Fever Virus (DENV) Illness Among Household Members Aged 6 Months to 50 Years of Selected Communities in Latin America and Southeast Asia
Not Applicable
Terminated
- Conditions
- Dengue VaccinesDengue
- Interventions
- Procedure: Blood sample collection
- First Posted Date
- 2016-05-09
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1750
- Registration Number
- NCT02766088
- Locations
- 🇵🇭
GSK Investigational Site, Muntinlupa, Philippines
© Copyright 2025. All Rights Reserved by MedPath